Profil
Emmanuelle Charpentier is the founder of CRISPR Therapeutics AG, founded in 2013, and ERS Genomics Ltd., founded in 2014.
At ERS Genomics Ltd., she holds the title of Scientific Advisor, which she has held since 2014.
Aktive Positionen von Emmanuelle Charpentier
| Unternehmen | Position | Beginn |
|---|---|---|
ERS Genomics Ltd.
 ERS Genomics Ltd. BiotechnologyHealth Technology ERS Genomic Ltd. engages in the development of biotechnology. It was formed to provide broad access to the foundational CRISPR-Cas9, a new genome editing technology, which offers speed, efficiency, and cost over earlier genome editing methods. The company was founded by Emmanuelle Charpentier and Shaun Foy in 2014 and is headquartered in Dublin, Ireland. | Gründer | 01.01.2014 |
Ehemalige bekannte Positionen von Emmanuelle Charpentier
| Unternehmen | Position | Ende |
|---|---|---|
| CRISPR THERAPEUTICS AG | Gründer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CRISPR THERAPEUTICS AG | Health Technology |
| Private Unternehmen | 1 |
|---|---|
ERS Genomics Ltd.
ERS Genomics Ltd. BiotechnologyHealth Technology ERS Genomic Ltd. engages in the development of biotechnology. It was formed to provide broad access to the foundational CRISPR-Cas9, a new genome editing technology, which offers speed, efficiency, and cost over earlier genome editing methods. The company was founded by Emmanuelle Charpentier and Shaun Foy in 2014 and is headquartered in Dublin, Ireland. | Health Technology |
